Results 1 to 10 of about 655,529 (373)

Spot‐14 and its paralog Spot‐14R regulate expression of metabolic and thermogenic pathway genes in murine brown and beige adipocytes

FEBS Letters, EarlyView.
Spot‐14 and Spot‐14R play distinct roles in regulating metabolism in brown and beige adipocytes. While both influence lipid and glucose pathways, Spot‐14 uniquely controls thermogenic gene expression. This dual regulation balances energy storage and heat production, highlighting potential therapeutic targets for obesity and metabolic disorders. Spot 14
Lidia Itzel Castro‐Rodríguez, Cristina Velez‐delValle, Claudia Patricia Hernández‐Mosqueira, Walid Kuri‐Harcuch   +3 more
wiley   +1 more source

Autophagy in cancer and protein conformational disorders

FEBS Letters, EarlyView.
Autophagy plays a crucial role in numerous biological processes, including protein and organelle quality control, development, immunity, and metabolism. Hence, dysregulation or mutations in autophagy‐related genes have been implicated in a wide range of human diseases.
Sergio Attanasio
wiley   +1 more source

Flow‐based immunomagnetic enrichment of circulating tumor cells from diagnostic leukapheresis product

Molecular Oncology, EarlyView.
The number of circulating tumor cells obtained from prostate cancer patients was increased approximately 5‐fold compared to regular CellSearch when processing 2 mL diagnostic leukapheresis material aliquots and increased by 44‐fold when processing 20 mL DLA aliquots using the flow enrichment target capture Halbach‐array.
Michiel Stevens, Anouk Mentink, Frank A. W. Coumans, Eshwari Dathathri, Khrystany T. Isebia, Jaco Kraan, Ronald de Wit, John W. M. Martens, Leon W. M. M. Terstappen   +8 more
wiley   +1 more source

Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors

Molecular Oncology, EarlyView.
Cell‐free microRNAs (cfmiRs) are small‐RNA circulating molecules detectable in almost all body biofluids. Innovative technologies have improved the application of cfmiRs to oncology, with a focus on clinical needs for different solid tumors, but with emphasis on diagnosis, prognosis, cancer recurrence, as well as treatment monitoring.
Yoshinori Hayashi, Janelle‐Cheri Millen, Romela Irene Ramos, Jennifer A. Linehan, Timothy G. Wilson, Dave S. B. Hoon, Matias A. Bustos   +6 more
wiley   +1 more source

Crosstalk between gut microbiota and tumor: tumors could cause gut dysbiosis and metabolic imbalance

Molecular Oncology, EarlyView.
In this research, we analyzed the relationship between gut microbiota and tumor. We discovered that both subcutaneous and metastatic tumors would alter the composition and metabolic function of gut microbiota. Meanwhile, fecal microbiota transplantation also indicated the anti‐tumor role of the gut microbiota, revealing the crosstalk between tumor and ...
Siyuan Zhang, Haimei Wen, Ying Chen, Jingya Ning, Di Hu, Yujiao Dong, Chenyu Yao, Bo Yuan, Shuanying Yang   +8 more
wiley   +1 more source

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Bioengineering facets of the tumor microenvironment in 3D tumor models: insights into cellular, biophysical and biochemical interactions

FEBS Open Bio, EarlyView.
The tumor microenvironment is a dynamic, multifaceted complex system of interdependent cellular, biochemical, and biophysical components. Three‐dimensional in vitro models of the tumor microenvironment enable a better understanding of these interactions and their impact on cancer progression and therapeutic resistance.
Salma T. Rafik, Deniz Bakkalci, Alexander J. MacRobert, Umber Cheema   +3 more
wiley   +1 more source

Advanced glycation end products promote the release of endothelial cell‐derived mitocytosis

FEBS Open Bio, EarlyView.
Under diabetic conditions, AGEs induce mitochondrial damage in HUVECs, activating migrasome‐mediated mitocytosis. Migrasomes encapsulate damaged mitochondria and are released into the extracellular space, facilitating intercellular mitochondrial transfer.
Rong Liu, Yuhao Zhang, Tiantian Ge, Hao Wu, Yongbin Ma, Honghua Ye, Fei Guo   +6 more
wiley   +1 more source

The impact of frailty syndrome on skeletal muscle histology: preventive effects of exercise

FEBS Open Bio, EarlyView.
Frailty syndrome exacerbates skeletal muscle degeneration via increased ECM deposition and myofiber loss. This study, using a murine model, demonstrates that endurance exercise attenuates these histopathological alterations, preserving muscle integrity. Findings support exercise as a viable strategy to counteract frailty‐induced musculoskeletal decline
Fujue Ji, Hae Sung Lee, Haesung Lee, Jong‐Hee Kim   +3 more
wiley   +1 more source

Knockout of the mitoribosome rescue factors Ict1 or Mtrfr is viable in zebrafish but not mice: compensatory mechanisms underlying each factor's loss

FEBS Open Bio, EarlyView.
Mitochondria contain two mitoribosome rescue factors, ICT1 and MTRFR (C12orf65). ICT1 also functions as a mitoribosomal protein in mice and humans, and its loss is lethal. Although Mtrfr knockout mice could not be generated, knockout zebrafish lines for ict1 and mtrfr were established.
Nobukazu Nameki, Chika Tomisawa, Soichiro Hoshino, Hidehiko Shimizu, Masashi Abe, Sho Arai, Kanako Kuwasako, Naoki Asakawa, Yusuke Inoue, Takuro Horii, Izuho Hatada, Masakatsu Watanabe   +11 more
wiley   +1 more source